Brand and generics companies unite to pressure FDA: they want the agency to drop its safety-label plan and adopt their alternative

Barlas S. Pharmacy and therapeutics 2015; 40(8):501-503

ARTICLE IDENTIFIERS

DOI: unavailable PMID: 26236138 PMCID: PMC4517532

JOURNAL IDENTIFIERS

LCCN: not available pISSN: 1052-1372 eISSN: not available OCLC ID: 22095729 CONS ID: not available US National Library of Medicine ID: 9015516

This article was identified from a query of the SafetyLit database.